MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2020

    Real-World Deutetrabenazine Dosing Patterns in Patients With Huntington’s Disease or Tardive Dyskinesia

    R. Ayyagari, A. Wilhelm, J. Alexander, N. Chaijale, V. Garcia-Horton, F. Devine, B. Carroll (Boston, MA, USA)

    Objective: To evaluate real-world treatment patterns and adherence to deutetrabenazine (DTBZ) in patients with Huntington’s disease (HD) or tardive dyskinesia (TD). Background: DTBZ is a…
  • MDS Virtual Congress 2020

    The Impact of Antipsychotic Dose Reduction Within a Medicare Population

    R. Ayyagari, F. Mu, A. Lax, B. Carroll (Boston, MA, USA)

    Objective: To analyze the burden of antipsychotic (AP) dose reduction in Medicare patients with schizophrenia (SZ). Background: Tardive dyskinesia (TD) develops in patients treated with…
  • MDS Virtual Congress 2020

    Deutetrabenazine Reduces Involuntary Movements in Patients Most Severely Impacted by Tardive Dyskinesia in a 3-year Open-Label Extension Trial

    J. Bona, H. Barkay, A. Wilhelm, N. Chaijale, M. Gordon (Atlanta, GA, USA)

    Objective: To evaluate the efficacy of deutetrabenazine (DTBZ) in reducing TD in the most severely impacted patients using data from an ongoing open-label extension (OLE)…
  • MDS Virtual Congress 2020

    An Open-Label, Phase 1b Study of the Neuroactive Steroid GABAA Receptor Positive Allosteric Modulator SAGE-324 in Essential Tremor

    H. Colquhoun, D. Nguyen, M. Qin, A. Wehr, J. Doherty, S. Kanes (Cambridge, MA, USA)

    Objective: This single dose, open-label, Phase 1b study assessed the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SAGE-324 in otherwise healthy patients with Essential…
  • MDS Virtual Congress 2020

    Long-Term Treatment With Deutetrabenazine (DTBZ) Is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From the Completed, 3-year Open-Label Extension (OLE) Study

    R. Hauser, H. Barkay, H. Fernandez, S. Factor, J. Jimenez-Shahed, N. Gross, L. Marinelli, A. Wilhelm, M. Gordon, J.M Savola, K. Anderson (Tampa, FL, USA)

    Objective: To evaluate long-term efficacy and safety of DTBZ in patients with TD by examining change from baseline in Abnormal Involuntary Movement Scale (AIMS) scores…
  • MDS Virtual Congress 2020

    Inosine 5′-Monophosphate to Raise the Serum Uric Acid Level in Patients with Multiple System Atrophy (IMPROVE-MSA study): A Multi-center, Randomized, Double Blind, Placebo-controlled, Parallel Assigned Clinical Trial

    J.J Lee, J.H Yoon, S.J Kim, H.S Yoo, S.J Chung, Y.H Lee, S.Y Kang, H.W Shin, S.K Song, J.Y Hong, M.K Sunwoo, J.E Lee, J.S Baik, Y.H Sohn, P.H Lee (Goyang-si, Republic of Korea)

    Objective: To investigate the safety, tolerability, and capability of serum uric acid (UA) elevation of inosine 5'-monophosphate (IMP) in multiple system atrophy (MSA). Background: Converging…
  • MDS Virtual Congress 2020

    High-frequency rTMS over the primary motor cortex relieves musculoskeletal pain in Parkinson’s disease: A randomized controlled trial

    J. Li, T. Mi, W. Mao, J. Ma, P. Chan (Beijing, China)

    Objective: To study the effects of high-frequency repetitive transcranial magnetic stimulation (rTMS) over primary motor cortex(M1) on musculoskeletal pain(MSP) in patients with Parkinson’s disease. Background:…
  • MDS Virtual Congress 2020

    Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Lower Limb Spasticity in Japanese Subjects

    Y. Masakado, A. Dekundy, A. Hanschmann, R. Kaji (Kanagawa, Japan)

    Objective: To confirm the efficacy and safety of incobotulinumtoxinA (INCO; Xeomin®, Merz Pharmaceuticals GmbH) in East Asian subjects from study sites in Japan with post-stroke…
  • MDS Virtual Congress 2020

    Long-term safety and efficacy of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects: results of a Phase III study

    F. Pagan, A. Dekundy, M. Althaus, D. Mitsikostas (Washington, DC, USA)

    Objective: To assess the safety and efficacy of incobotulinumtoxinA for benign essential blepharospasm (BEB) in toxin-naïve subjects. Background: IncobotulinumtoxinA is efficacious for BEB. This was…
  • MDS Virtual Congress 2020

    Long-term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia

    M. Sajatovic, A. Wilhelm, S. Finkbeiner, H. Barkay, N. Chaijale, N. Gross, M. Gordon (Cleveland, OH, USA)

    Objective: To assess the long-term safety and efficacy of deutetrabenazine in younger (<55 years) and older (≥55 years) patients with tardive dyskinesia (TD). Background: TD…
  • « Previous Page
  • 1
  • …
  • 761
  • 762
  • 763
  • 764
  • 765
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley